layoffs

Black Diamond Therapeutics to Discontinue ErbB Inhibitor Program, Lay Off 30 Percent of Workforce

The company is shifting its focus to developing EGFR and BRAF inhibitors and believes cutting staff will extend its cash runway into Q3 2024.

Silverback Discontinues Targeted Oncology Programs, Reduces Staff

The company terminated development of two antibody-drug conjugates due to lackluster anti-tumor activity and cytokine-related adverse events.

Ziopharm Oncology Restructures to Focus on Advancing Autologous T-Cell Receptor Therapies

The firm has cut over half of its positions and plans to use its cash to generate data for its TCR-T Library program and construct in-house manufacturing facilities.

layoffs

Black Diamond Therapeutics to Discontinue ErbB Inhibitor Program, Lay Off 30 Percent of Workforce

Silverback Discontinues Targeted Oncology Programs, Reduces Staff

Ziopharm Oncology Restructures to Focus on Advancing Autologous T-Cell Receptor Therapies

In Brief This Week: AstraZeneca, Merck, Stemline Therapeutics, Caris Life Sciences, Artios Pharma

AstraZeneca, Daiichi Sankyo's Enhertu Scores FDA Accelerated Approval in HER2-Mutant Lung Cancer

Novartis' Tabrecta Nets Full FDA Approval for NSCLC With METex14 Skipping Mutations

Clarified Precision Medicine, VieCure Partner to Make Precision Oncology Expertise More Accessible

Roche Nabs FDA Label Expansion for Ventana CDx Panel

Bristol Myers Squibb, 2seventy Bio Eyeing Earlier-Line Multiple Myeloma Abecma Indication